CME webinar: Intimate Partner Violence: Driving Forward Toward Solutions (recorded)
Sep. 2023Important Notices
Marlex Pharmaceuticals Inc. is recalling two lots of this drug because of a label mix-up. Bottles of Digoxin Tablets USP 0.125 mg are incorrectly labeled and contain Digoxin Tablets USP 0.25 mg. Bottles of Digoxin Tablets USP 0.25 mg are incorrectly labeled and contain Digoxin Tablets USP 0.125 mg. This drug is used for the treatment of mild to moderate heart failure. Read the full text of the voluntary Digoxin recall.
Recent Announcements
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates
HelpScript service helps patients enroll in manufacturer copay assistance programs
End-to-end provider support helps ensure a smooth submission processOct. 2025Important Notices
Important announcement – Telehealth submissions
As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.Sep. 2025Important Notices